Mindfulness based stress reduction, developed by Jon Kabat Zinn at the University of Massachusetts in the 1970s, was among the first structured applications of mindfulness practice to clinical populations. In the decades since, the research base has expanded substantially , and so has the commercial ecosystem around mindfulness, which now encompasses apps, corporate wellness programs, and a range of products that claim mindfulness benefits with varying evidentiary support. Separating the signal from the noise requires looking at study quality, population specificity, and outcome measures.
Where the evidence is strongest
The strongest evidence for mindfulness based interventions is in the prevention of depressive relapse. Mindfulness based cognitive therapy (MBCT) , which combines mindfulness practice with cognitive therapy elements , has been shown in multiple randomized trials to reduce the risk of depression recurrence in people with three or more prior depressive episodes by roughly 40 50%, an effect comparable to maintenance antidepressants. Evidence for anxiety, chronic pain, and stress related conditions is moderately strong. Evidence for acute depression treatment, psychosis, and trauma related conditions is more mixed and requires careful clinical judgment. The app based mindfulness market runs substantially ahead of its evidence base.
